Nitroglycerin Patent Expiration
Nitroglycerin was first introduced by Hospira Inc
Nitroglycerin Patents
Given below is the list of patents protecting Nitroglycerin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gonitro | US9101592 | Stabilized granules containing glyceryl trinitrate | Mar 11, 2032 | Pohl Boskamp |
| Nitrolingual Pumpspray | US7872049 | Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate | Mar 12, 2029 | Pohl Boskamp |
| Nitrostat | US6500456 | Compressed nitroglycerin tablet and its method of manufacture |
Sep 16, 2018
(Expired) | Viatris |
| Nitromist | US5869082 | Buccal, non-polar spray for nitroglycerin |
Apr 16, 2016
(Expired) | Evus |
| Rectiv | US7189761 | Nitric oxide donor composition and method for treatment of anal disorders |
May 27, 2014
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Nitroglycerin's patents.
Latest Legal Activities on Nitroglycerin's Patents
Given below is the list recent legal activities going on the following patents of Nitroglycerin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 15 Apr, 2019 | US7189761 |
| Maintenance Fee Reminder Mailed Critical
| 29 Oct, 2018 | US7189761 |
| Recordation of Patent Grant Mailed Critical
| 13 Mar, 2007 | US7189761 |
| Patent Issue Date Used in PTA Calculation Critical
| 13 Mar, 2007 | US7189761 |
| Issue Notification Mailed Critical
| 21 Feb, 2007 | US7189761 |
| Application Is Considered Ready for Issue Critical
| 30 Jan, 2007 | US7189761 |
| Dispatch to FDC | 30 Jan, 2007 | US7189761 |
| Issue Fee Payment Verified Critical
| 26 Jan, 2007 | US7189761 |
| Issue Fee Payment Received Critical
| 26 Jan, 2007 | US7189761 |
| Mail Notice of Allowance Critical
| 30 Oct, 2006 | US7189761 |
Nitroglycerin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Nitroglycerin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease | Bayer | NA |
NOT YET RECRUITING
(Aug 4, 2026)
| PHASE1 |
| Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension | Vanderbilt University | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | University of California, San Francisco | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE2 |